Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
| Autor: | Tuğba Aydoğan, Gurkan Erdogan, Ahmet Bahadir Ergin, Cihan Ünlü |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
intravitreal bevacizumab
medicine.medical_specialty Visual acuity genetic structures lcsh:Medicine 03 medical and health sciences 0302 clinical medicine lcsh:Ophthalmology Ophthalmology Type 2 idiopathic macular telangiectasia medicine In patient Intravitreal bevacizumab Macular edema Macular telangiectasia medicine.diagnostic_test business.industry lcsh:R medicine.disease Dilated fundus examination Fluorescein angiography eye diseases lcsh:RE1-994 Decreased Visual Acuity 030221 ophthalmology & optometry Original Article sense organs medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Turkish Journal of Ophthalmology Türk Oftalmoloji Dergisi, Vol 46, Iss 6, Pp 270-273 (2016) |
| ISSN: | 1300-0659 |
| DOI: | 10.4274/tjo.23921 |
| Popis: | Objectives: To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT). Materials and Methods: Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an ophthalmological examination including best corrected visual acuity (BCVA), dilated fundus examination, spectral domain optical coherence tomography (OCT) and fluorescein angiography. Intravitreal bevacizumab injection was planned for patients who had macular edema and/or decreased visual acuity at baseline. Patients were examined 1 week and 1 month after the intravitreal injection. Intravitreal injection was repeated in patients whose visual acuity decreased and/or whose macular edema persisted or increased. Changes in BCVA, central macular thickness (CMT) and central macular volume from baseline at 1 month after the first injection and at final examination were evaluated. Results: Average age of the patients (4 female and 1 male) was 62±11.8 years. Average follow-up period was 26±11 months. Patients received an average of 2.3 (range 1-4) injections during follow-up. Average Snellen BCVA of the patients was 0.48±0.29. BCVA increased at final examination compared to baseline in all of the patients. The difference between baseline and final visual acuities was significant (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|